Novorapid Innolet (Insulin Aspart)

Insulin aspart is a modified form of human insulin that binds to insulin receptors on muscle, fat and liver cells. This binding activates intracellular signaling pathways that promote the movement of glucose transporters to the cell surface, increasing glucose uptake from the bloodstream and suppressing hepatic glucose production, thereby lowering blood sugar levels quickly after injection.

The dose of Novorapid Innolet is individualized by the prescribing healthcare professional based on factors such as the patient’s current blood glucose readings, carbohydrate intake, body weight, renal function, and overall treatment goals. No fixed dosing regimen can be provided; the prescriber adjusts the amount and timing to achieve optimal glycaemic control.

The pregnancy category for insulin aspart is not definitively established, and data are limited. Insulin therapy is often required during pregnancy to maintain maternal glucose control, but the decision to use Novorapid Innolet should be made by a qualified obstetrician or endocrinologist after weighing potential benefits against unknown risks. Breastfeeding mothers should also consult their clinician.

To place an order, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity of Novorapid Innolet. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details—including cold‑chain logistics where applicable—and necessary import documentation.

Novorapid Innolet (insulin aspart) shares a rapid onset and short duration profile with other rapid‑acting analogues such as insulin lispro and insulin glulisine. Clinical studies show comparable efficacy in post‑prandial glucose reduction, while individual patient response, formulation characteristics, and device compatibility may influence the choice of one analogue over another.

Novorapid Innolet should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing. Once opened, the solution may be kept at controlled room temperature (up to 25 °C) for a maximum of 28 days, after which any remaining product should be discarded.

Novorapid Innolet is administered by subcutaneous injection, usually into the abdomen, thigh, or upper arm. It is typically injected within 15 minutes before a meal or immediately after eating, depending on the prescriber’s instructions. Patients should rotate injection sites to reduce the risk of lipodystrophy and follow aseptic technique for each dose.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood sugar, monitor glucose levels regularly, and seek immediate medical attention if they experience symptoms of a severe allergic response.

Novorapid Innolet should be avoided in individuals with a known hypersensitivity to insulin aspart or any of the excipients in the formulation. It is also contraindicated in patients experiencing hypoglycemia unawareness where rapid‑acting insulin could exacerbate the condition without proper monitoring. Clinical judgment is required for patients with severe renal or hepatic impairment.